What to Expect When Mylan (MYL) Reports Fourth Quarter Earnings Today
NEW YORK (TheStreet) -- Shares of Mylan (MYL) - Get Report are up 0.29% to $57.49 in afternoon trading ahead of the company's fourth quarter earnings report expected after the market close today.
The consensus estimate calls for the Canonsburg, PA-based pharmaceuticals company to report earnings of $1.05 a share on revenue of $2.07 billion.
In the fourth quarter of last year, the company posted earnings of 78 cents a share, above the consensus estimate for earnings of 75 cents a share, according to analysts polled by Reuters. Revenue totaled $1.808 billion, just above analysts' estimates of $1.807 billion.
Exclusive Report:Jim Cramer's Best Stocks for 2015
In the third quarter of 2014, Mylan's earnings of $1.16 beat estimates of $1.14. Revenue totaled $2.08 billion, above estimates of $2.06 billion.
The average recommendation of 16 brokers' estimates on the stock is 2.1, with a 2 representing an "outperform" rating and 3 a "hold," according to Reuters. The mean price target is $59.56.
Separately, the company recently announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, entered into an agreement with Gilead Sciences (GILD) - Get Report , under which Mylan was appointed as the exclusive distributor of Sovaldi and Harvoni for the treatment of chronic hepatitis C, in India.
Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty.
TheStreet Ratings team rates MYLAN INC as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
"We rate MYLAN INC (MYL) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."
You can view the full analysis from the report here: MYL Ratings Report